NewGenIvf Group Limited cash flow to debt ratio of -224.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NewGenIvf Group Limited's free cash flow has decreased 100.50% from $-8.32M last year to $-16.68M, signaling decreasing performance

NewGenIvf Group Limited's debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

NewGenIvf Group Limited's debt has increased relative to shareholder equity from -2.89 last year to 0.18 today, signaling weakened financials

NewGenIvf Group Limited has a net debt to EBITDA ratio of 0.38x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

NewGenIvf Group Limited's interest coverage ratio is -15.25, which means that the company struggles to meet interest obligations, signaling financial risk.

NewGenIvf Group Limited's profit margin has increased (-3.60K%) in the last year from -9.66% to 338.20%, signaling increasing performance

NewGenIvf Group Limited's short-term assets of $7.38M exceed its short-term liabilities of $2.37M

NewGenIvf Group Limited's return on assets of 27.98% is higher than the 5.00% threshold, indicating efficient asset utilization

NewGenIvf Group Limited's return on equity of 32.69%, is higher than 15.00%, indicating good performance

NewGenIvf Group Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NewGenIvf Group Limited had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

NewGenIvf Group Limited has negative free cash flow, indicating the company is burning cash rather than generating it

NewGenIvf Group Limited has negative free cash flow, indicating cash burn

NewGenIvf Group Limited's yearly earnings has increased -1.98K% since last year from $-525.00K to $9.88M, signaling increasing performance

NewGenIvf Group Limited's yearly revenue has decreased -13.01% since last year from $5.43M to $4.73M, signaling decreasing performance

ROIC -24.27% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

NewGenIvf Group Limited's 3-year revenue CAGR of -7.36% is negative, indicating declining revenue over the past 3 years

NewGenIvf Group Limited had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

NewGenIvf Group Limited had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity

NewGenIvf Group Limited has insufficient data to evaluate this check.

NewGenIvf Group Limited has an earnings yield of 3.26K%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

NewGenIvf Group Limited is undervalued relative to its fair value price of 126.33 based on EBITDA multiple model

NewGenIvf Group Limited has an EV/EBITDA ratio of 0.40x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

NewGenIvf Group Limited has insufficient data to evaluate this check.

NewGenIvf Group Limited has a PEG-ratio under 1 which is considered undervalued

NewGenIvf Group Limited has a price-to-book ratio of 0.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

NewGenIvf Group Limited has a price-to-sales ratio of 0.10x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue